GSK-239512

• CAT Number: I007088
• CAS Number: 720691-69-0
• Molecular Formula: C23H27N3O2
• Molecular Weight: 377.49
• Purity: ≥95%
• Synonyms: GSK-239512; GSK239512; GSK 239512;;2-Pyrrolidinone, 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-
• Target: Neuronal Signaling
• Solubility: Soluble in DMSO
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: 1-[6-[(3-cyclobutyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)oxy]pyridin-3-yl]pyrrolidin-2-one
• InChI: InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
• InChIKey: YFRBKEVUUCQYOW-UHFFFAOYSA-N
• SMILES: C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O

GSK-239512（Cat No.:I007088）is a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4), which plays a key role in the regulation of inflammation and immune responses. By inhibiting PDE4, GSK-239512 reduces the breakdown of cyclic AMP (cAMP), leading to increased anti-inflammatory effects. It has shown potential in preclinical and clinical trials for treating inflammatory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and rheumatoid arthritis. GSK-239512 may offer a novel approach to managing these conditions by targeting specific inflammatory pathways, though further studies are needed to confirm its efficacy and safety.